Rhabdomyosarcoma (RMS) is the third most common solid tumor in children and is often associated with high morbidity and mortality. The heterogenous nature of RMS along with the lack of genetically accurate mouse models has precluded this cancer from many of the therapy testing strategies currently being used for other malignancies. We hope to develop a mouse model that will accurately recapitulate the human disease including genetic heterogeneity and metastatic potential. These mice will allow testing for further classification of tumors that will aid in treatment decisions and be use to test novel therapies in pre-clinical trials for RMS treatment.
Dawn Chandler, PhD, Children’s Research Institute
Recipient of the: $25,000 Jake’s Reindeer Race/Maynard Family Research Award